Tolcapone, bromocriptine, and Parkinson's disease [3]

Lancet

Volumn 350, Issue 9079, 1997, Pages 712-713

  Agid, Y ^a   Destee A ^b   Durif, F ^b   Montastruc, J L ^b   Pollak, P ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; LEVODOPA; TOLCAPONE;

CLINICAL TRIAL; DOPAMINERGIC ACTIVITY; DYSTONIA; HALLUCINATION; HUMAN; LETTER; MOTOR PERFORMANCE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; XEROSTOMIA;

EID: 0030794892     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)63511-8     Document Type: Letter

References (5)

1. LeWitt PA. Treatment strategies for extension of levodopa effect. Neurol Clin 1992; 10; 511-26.
2. Montastruc J-L, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993; 46; 384-93.
3. Tolosa ES, Valldeoriola F, Martí MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994; 44 (suppl 6): S35-S44.
4. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995; 18: 333-37.
5. Kurth MC, Adler CH, Saint Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997; 48; 81-87.